NURIFLEX-HOLDINGS
6.1.2022 18:02:07 CET | Business Wire | Press release
NuriFlex Holdings Inc. (“NuriFlex Holdings ”) announced that it has signed a memorandum of understanding (“MoU ”) with Talken GmbH (“Talken ”). The two companies intend to collaborate in the metaverse token project and the multichain decentralized NFT wallet and its platform (“Project”) in various regions based on robust technology and business development capabilities of the parties.
One of NuriFlex Holdings’ businesses involves the design and development of a blockchain-based metaverse ecosystem to offer various virtual worlds and related digital experiences for various services. NuriFlex Holdings is currently investing in the metaverse project that is expected to launch this year, offering global users participation in its virtual metaverse world where they can create and interact with other users like in real life.
Talken GmbH provides a service called ‘Talken’, which is a multi-chain decentralized NFT wallet supported by one of the largest Korean communities. It is a seamlessly interoperable multi-chain NFT Suite, where K-pop stars, artists, and influencers can mint, auction, store, and trade NFTs. Talken NFT Suite offers various products for every NFT lifecycle stage such as NFT wallet, NFT marketplace, simple NFT minting tool and more.
“We are excited to partner and collaborate with Talken GmbH on our metaverse and NFT platform projects. The blockchain technology experience and business development capabilities that NuriFlex Holdings and Talken GmbH bring together will be a great advantage to successfully accomplish new business opportunities and the initial step to our future token projects,” said Songman Cho, Chairman of NuriFlex Holdings Inc.
“We hope this will be the first of many partnerships to come between Nuri Group and Talken. I trust there will be many synergies to be made between Nuri’s solution for blockchain-based digital services and Talken’s unique multichain NFT platform,” said Minsu Ju, Chief Executive Officer of Talken GmbH.
About NuriFlex Holdings Inc.
Located in Vancouver, BC, Canada, NuriFlex Holdings Inc. is a parent company to the Nuri Group of companies, including NuriFlex Inc. in the USA and NuriFlex Co., Ltd. in South Korea. The NuriFlex Group of companies utilize telecommunication technologies and applications to supply a simple, convergent solution for the utilities industry, payment solution and blockchain-based digital service platform. We provide a complete energy IoT solution which enhances the utility of connected micro and smart grids throughout our clients’ systems. The blockchain embedded solution and service will be NuriFlex Group’s next-generation business. Our existing solutions will be integrated with our blockchain technology to make us one of the top integrated solution providers in the international market. Learn more at www.nuri.ca
About Talken GmbH
Talken is the multi-chain decentralized NFT wallet with the largest community. It is a seamlessly interoperable multi-chain NFT Suite, where K-pop stars, artists, and influencers can mint, auction, store, and trade NFTs. Talken is an open NFT ecosystem bridging untapped NFT enthusiasts in Korea to Talken’s native NFTs and other famous NFTs by protocols such as NBA TopShot, Rarible, OpenSea, and more. Our mission is to push for an inclusive and border-less NFT expansion and empower digital creators and collectors with better tools and services to bring NFT mainstream. Learn more at www.talken.io
View source version on businesswire.com: https://www.businesswire.com/news/home/20220107005002/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom